|Bid||26.99 x 800|
|Ask||27.05 x 1000|
|Day's range||26.32 - 27.66|
|52-week range||15.58 - 48.40|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||49.63|
FRIENDSWOOD, Texas, January 23, 2023--Castle's medical director, Matthew Goldberg, M.D., F.A.A.D., will present at the Precision Medicine World Conference (PMWC®) 2023 on Jan. 25.
FRIENDSWOOD, Texas, January 17, 2023--Castle is sharing new data supporting the clinical value of their skin cancer tests at the 2023 Winter Clinical Dermatology Conference - Hawaii®.
FRIENDSWOOD, Texas, January 09, 2023--Castle Biosciences today announced certain unaudited preliminary performance results for the fourth quarter and full-year ended Dec. 31, 2022.